{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-000093","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.306369+00:00","generated_at":"2026-05-28T05:07:32.158827+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rhythm Pharma reports preliminary 2024 IMCIVREE sales of $130M, up 68% YoY; Phase 3 HO data on track for H1 2025","bullets":["Preliminary Q4 2024 IMCIVREE net revenues of ~$42M, up 26% sequentially; full year ~$130M vs $77.4M in 2023.","U.S. sales contributed ~74% of Q4 and ~73% of full year 2024 revenues.","Topline data from Phase 3 acquired hypothalamic obesity trial expected in first half of 2025; completed Japanese cohort.","Phase 3 EMANATE enrollment completed across four substudies; topline data anticipated first half of 2026.","New Phase 2 trial of setmelanotide in Prader-Willi syndrome to initiate Q1 2025 (up to 20 patients, 26 weeks)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-000093","json":"https://secwatch.observer/filing/0001558370-25-000093.json","markdown":"https://secwatch.observer/filing/0001558370-25-000093.md","text":"https://secwatch.observer/filing/0001558370-25-000093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/0001558370-25-000093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:07:32.158827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}